Coronary Artery DiseaseNCT01114269
PRE-DETERMINE Cohort Study
An observational study of Coronary Artery Disease and Left Ventricular Dysfunction, run by Brigham and Women's Hospital at 90 sites in 3 countries.
Trial summary
This is a prospective, multi-center cohort study of patients with a history of coronary artery disease (CAD) and documentation of either a prior myocardial infarction (MI) or mild to moderate left ventricular dysfunction (LVEF 35-50%). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Artery Disease, Left Ventricular Dysfunction, Sudden Cardiac Death
- How many people
- 5,764 participants
- Where
- 90 sitesin 3 countries
- Study dates
- Jul 2007to Nov 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants have been recruited throughout multicenter sites participating in the PRE-DETERMINE Cohort Study. Patients with a history of coronary artery disease and documentation of either a prior myocardial infarction (MI) or mild to moderate left ventricular dysfunction (LVEF 35-50%) have been enrolled. The clinical study staff at each site, which was either a research nurse, fellow, or physician approached eligible patients to discuss their potential participation.
Who may be able to join
- Evidence of Coronary Artery Disease (CAD) a or documented prior Myocardial Infarction.
- LVEF >35% by any current standard evaluation technique (e.g.,) echocardiogram, MUGA, angiography). 2.1. Patients who have an LVEF between 30-35% and NYHA Class I heart failure who do not have history of ventricular tachyarrhythmias,or inducible ventricular tachycardia during electrophysiological (EP) testing can be enrolled.
- If documented prior MI is not present, evidence of mild-moderate systolic Left Ventricular Dysfunction with an EF >35- ≤50% as measured by any current standard screening technique (e.g.,echocardiogram, MUGA, angiography) must be present.
- Patients aged 18 years or above
- CAD will be defined as evidence of one of the following two (2) criteria:
- Significant stenosis of a major epicardial vessel (>50% proximal or 70% distal) by coronary angiography
Show all 16Show fewer
- Prior revascularization (percutaneous coronary intervention or coronary artery bypass surgery)
- MI can be documented in the following ways:
- From the MI hospitalization: Detection of a rise and fall of cardiac biomarkers > 99th percentile of lab (e.g., CPK elevation or Troponin at least > two times the upper limit of normal) together with myocardial ischemia with at least one of the following:
- Symptoms of Ischemia
- ECG changes indicative of new ischemia (new ST-T changes or new LBBB)
- Development of pathological Q waves
- Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality
- If no report from the MI hospitalization is available, prior MI can be met by either of the following:
- Development of pathological Q waves
- Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischaemic cause
Who cannot join
- History of cardiac arrest or spontaneous or inducible sustained VT (15 beats or more at a rate of 120 BPM or greater - the occurrence of cardiac arrest or spontaneous VT in the setting of an acute MI is not considered an exclusion).
- Unexplained syncope
- Current or planned implantable cardiac defibrillator (ICD)
- Any condition other than cardiac disease that, in the investigator's judgment, would seriously limit life expectancy (poor survival)
- Metastatic cancer
- Marked valvular heart disease requiring surgical intervention
Show all 11Show fewer
- Current or planned cardiac, renal or liver transplant
- Current alcohol or drug abuse
- Unwilling or unable to provide informed consent
- LVEF <35% with Class II-IV CHF or LVEF <30%
- Participation in a clinical trial where the active treatment arm is testing an agent and/or intervention with known antiarrhythmic properties
Trial locations and contacts
90 sites in 3 countries.
90 sites in 3 countries
United States86 sites
Abington Memorial Hospital
Abington, Pennsylvania, 19001
Northeast Ohio Cardiovascular Specialists
Akron, Ohio, 44304
Albany Associates Cardiology
Albany, New York, 12205
New Mexico VA Healthcare Systems
Albuquerque, New Mexico, 87108
Alaska Heart Institute
Anchorage, Alaska, 99508
Community Heart and Vascular
Anderson, Indiana, 46011
AnMed Health
Anderson, South Carolina, 29621
University of Michigan Medical Center
Ann Arbor, Michigan, 48109
Asheville Cardiology Associates
Asheville, North Carolina, 28801
Maine Research Associates
Auburn, Maine, 04210
Primary Care Cardiology Research
Ayer, Massachusetts, 01432
University of Maryland Medical Center
Baltimore, Maryland, 21201
Beaver Medical Group/Clinical Care Research
Banning, California, 92220
St. Luke's Bethlehem
Bethlehem, Pennsylvania, 18018
Brigham and Women's Hospital
Boston, Massachusetts, 02115
Bay Area Cardiology Associates, P.A.
Brandon, Florida, 33511
Advanced Heartcare, LLC
Bridgewater, New Jersey, 08807
Maimonides Medical Center
Brooklyn, New York, 11219
Buffalo General Hospital/Kaleida Health
Buffalo, New York, 14203
VA Medical Center - Charleston
Charleston, South Carolina, 29425
University of Chicago
Chicago, Illinois, 60637
Advocate Medical Group
Chicago, Illinois, 60643
Advocate Medical Group - Heart and Vascular of IL
Chicago, Illinois, 60657
University of Cincinnati
Cincinnati, Ohio, 45267
MetroHealth Medical Center
Cleveland, Ohio, 44109
Memorial Health System
Colorado Springs, Colorado, 80909
University of Missouri Health Care
Columbia, Missouri, 65201
Georgia Heart Specialist
Covington, Georgia, 30014
Oakwood Hospital & Medical Center
Dearborn, Michigan, 48124
Colorado Heart and Vascular
Denver, Colorado, 80204
Doylestown Cardiology Associates
Doylestown, Pennsylvania, 18901
Eastern Carolina Cardiovascular
Elizabeth City, North Carolina, 27909
North Ohio Research, Ltd.
Elyria, Ohio, 44035
Mercy Medical Associates
Fairfield, Ohio, 45014
NECCR Internal Medicine and Cardiology Associates, LLC
Fall River, Massachusetts, 02720
University of Florida - Gainsville
Gainesville, Florida, 32610
Northeast Georgia Heart Center, P.C.
Gainesville, Georgia, 30501
Phoenix Heart, PLLC
Glendale, Arizona, 85306
Leonard J. Chabert Medical Center
Houma, Louisiana, 70363
St. Luke's Episcopal Hospital
Houston, Texas, 77030
Non-Invasive Cardiovascular PA
Houston, Texas, 77074
Jamaica Hospital Medical Center
Jamaica, New York, 11418
Glacier View Cardiology
Kalispell, Montana, 59901
The University of Kansas
Kansas City, Kansas, 66160
Mid-Valley Cardiology
Kingston, New York, 12401
Cardiovasular Research of Knoxville
Knoxville, Tennessee, 37917
Northstate Clinical Research
Lenoir, North Carolina, 28645
Maine Research Associates - Lewiston
Lewiston, Maine, 04240
Baptist Health Lexington
Lexington, Kentucky, 40503
Consultants in Cardiovascular Medicine
Melrose Park, Illinois, 60160
Memphis VA Medical Center
Memphis, Tennessee, 38104
Reliable Clinical Research
Miami, Florida, 33135
Mount Sinai Medical Center
Miami Beach, Florida, 33140
Winthrop-University Hospital
Mineola, New York, 11501
Minneapolis VA Medical Center
Minneapolis, Minnesota, 55417
McLaren Medical Center - Macomb
Mount Clemens, Michigan, 48043
Intermountain Medical Center
Murray, Utah, 84157
Gotham Cardiovascular
New York, New York, 10001
Columbia University Health Center
New York, New York, 10032
Hawthorn Medical Associates
North Dartmouth, Massachusetts, 02747
Oklahoma City VA Medical Center Veterans Research and Education Foundation
Oklahoma City, Oklahoma, 73104
Oklahoma Foundation for Cardiovascular Research
Oklahoma City, Oklahoma, 73120
The Cardiac Center of Creighton University
Omaha, Nebraska, 68131
Florida Hospital
Orlando, Florida, 32804
Orlando Regional Medical Center
Orlando, Florida, 32806
Palm Beach Gardens Research Center
Palm Beach Gardens, Florida, 33410
St. Joseph Regional Medical Center
Paterson, New Jersey, 07503
Cardiovascular Consultants
Phoenix, Arizona, 85032
Pinehurst Medical Clinic, Inc.
Pinehurst, North Carolina, 28374
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213
Black Hills Cardiovascular Research
Rapid City, South Dakota, 57701
Carolina Cardiology Associates
Rock Hill, South Carolina, 29732
Sanford Cardiology
Sanford, North Carolina, 27330
Velella Research
Sarasota, Florida, 34233
Baystate Cardiology
Springfield, Massachusetts, 01199
Stony Brook University Medical Center
Stony Brook, New York, 11794
Tallahassee Research Institute, Inc.
Tallahassee, Florida, 32308
Northwest Ohio Cardiology Consultants/The Toledo Hospital
Toledo, Ohio, 43615
St. Elizabeth Medical Center - Hotvedt
Utica, New York, 13501
Cardiovascular Associates Virginia Beach
Virginia Beach, Virginia, 23454
Providence Health Center
Waco, Texas, 76712
Iowa Heart Center
West Des Moines, Iowa, 50266
Cardiology Associates of Palm Beach - West Palm Beach
West Palm Beach, Florida, 33401
Wake Forest
Winston-Salem, North Carolina, 27157
Michigan Heart
Ypsilanti, Michigan, 48197
Canada3 sites
University of Alberta
Edmonton, Alberta, T6G 2B7
Mississauga Clinical Research Centre
Mississauga, Ontario, L5B 2P7
Vancouver General Hospital
Vancouver, British Columbia, V5Z 1M9
Puerto Rico1 site
Transcatheter Medical, Inc. Centro Cardiovascular de Caguas y del Caribe
Rio Piedras, 00924
About this study
Official title: PRE-DETERMINE: Biologic Markers and MRI SCD Cohort Study
This is a prospective, multi-center cohort study of patients with a history of coronary artery disease (CAD) and documentation of either a prior myocardial infarction (MI) or mild to moderate left ventricular dysfunction (LVEF 35-50%). The primary objective of this study is to determine whether biologic markers and ECGs can be utilized to advance SCD risk prediction in patients with CHD and LVEF>30-35%. The overarching goal of the study is to identify a series of markers that alone or in combination specifically predict risk of arrhythmic death as compared to other causes of mortality among this at risk population of coronary heart disease (CHD) patients with preserved left ventricular ejection fraction (LVEF> 30-35%). If biologic or ECG markers are identified that can specifically predict risk of ventricular arrhythmias, then these markers may serve as relatively inexpensive methods to identify those at risk. The public health impact of identifying markers could be quite substantial, leading to more efficient utilization of ICDs and advances in our understanding of mechanisms underlying SCD.
Read the detailed description
The PRE-DETERMINE Study is a prospective, multi-center study of patients with a history of coronary artery disease (CAD) and documentation of either a prior myocardial infarction (MI) or mild to moderate left ventricular dysfunction (LVEF 35-50%). Patients were enrolled at 135 sites where information on baseline demographics, clinical characteristics, pertinent past medical history, lifestyle habits, cardiac test results, and medications were collected via electronic data capture. Electrocardiograms along with a blood sample was also collected at baseline, sent to central laboratories, and stored for future analyses. Contrast-enhanced magnetic resonance imaging (CE-MRI) scans were collected on a subset of patients and analyzed. Enrollment closed in November 2013 and patients are now being followed centrally by the Clinical Coordinating Center via mail/phone to document interim non-fatal arrhythmic events and cause-specific mortality. Questionnaires that inquire about intervening ICD implantations, ICD therapies, cardiac arrest, and other pertinent cardiovascular endpoints are mailed to participants every six months, and follow-up telephone calls are made to non-responders. Study endpoints are being confirmed through review of medical records, interviews with next-of-kin, and autopsy reports, if available.
- Keywords
- Coronary Artery Disease, Sudden Cardiac Death, Myocardial Infarction, Percutaneous Coronary Intervention, Implantable Cardiac Defibrillator
- Medical subject headings
- Coronary Artery Disease, Ventricular Dysfunction, Left, Death, Sudden, Cardiac, Myocardial Infarction
What is being measured
The primary outcome is the main question the study is designed to answer.
Sudden and/or arrhythmic cardiac death or resuscitated ventricular fibrillation.
A definite sudden cardiac death (SCD) is defined as a death or fatal cardiac arrest occurring within 1 hour of symptom onset or the presence of autopsy consistent with SCD (e.g. acute coronary thrombosis). Probable SCD is defined as an unwitnessed death or death during sleep where the participant was observed to be symptom-free within the preceding 24 hours. Arrhythmic death is defined as the abrupt spontaneous collapse of circulation without antecedent circulatory or neurologic impairment. Deaths classified as non-arrhythmic are not included in the primary endpoint regardless of timing. Resuscitated ventricular fibrillation is defined as out-of-hospital cardiac arrests with documented VF and/or use of external electrical defibrillation for resuscitation.
Measured: Median follow-up estimated to be 10.7 years
Secondary outcomes (5)
ICD Shock
ICD therapies for ventricular arrhythmias over 200 BPMs will be added to the endpoint.
Measured: Median follow-up estimated to be 10.7 years
ICD Implantation
Measured: Median follow-up estimated to be 10.7 years
Total Cardiac Mortality
Measured: Median follow-up estimated to be 10.7 years
Total Mortality
Measured: Median follow-up estimated to be 10.7 years
Non-Sudden or Arrhythmic Causes of Mortality
Competing causes of mortality in competing risk analyses.
Measured: Median follow-up estimated to be 10.7 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 May 2010 (estimated)
- Study startJul 2007
- Primary completionNov 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- More trials run by Brigham and Women's HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5,764 participants (actual)
Sponsor and investigators
- Lead sponsor
- Brigham and Women's Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Abbott Medical Devices, Northwestern University, Quintiles, Inc., Roche Diagnostic Ltd., National Heart, Lung, and Blood Institute (NHLBI), Cedars-Sinai Medical Center
- Responsible party
- Principal investigator, Christine M. Albert, MD, MPH, Brigham and Women's Hospital
- Investigators
- Christine M Albert, M.D., M.P.H., Principal investigator, Brigham and Women's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01114269
- Sponsor's protocol ID
- 2007P000840
- Other IDs
- R01HL091069, R01HL165840
- Status last verified
- Oct 2025
- First submitted
- 29 Apr 2010
- Last updated
- 7 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Chatterjee NA, Moorthy MV, Pester J, Schaecter A, Panicker GK, Narula D, Lee DC, Goldberger JJ, Kadish A, Cook NR, Albert CM; PRE-DETERMINE Study Group. Sudden Death in Patients With Coronary Heart Disease Without Severe Systolic Dysfunction. JAMA Cardiol. 2018 Jul 1;3(7):591-600. doi: 10.1001/jamacardio.2018.1049.
PubMed 29801082Lee DC, Albert CM, Narula D, Kadish AH, Panicker GK, Wu E, Schaechter A, Pester J, Chatterjee NA, Cook NR, Goldberger JJ. Estimating Myocardial Infarction Size With a Simple Electrocardiographic Marker Score. J Am Heart Assoc. 2020 Feb 4;9(3):e014205. doi: 10.1161/JAHA.119.014205. Epub 2020 Jan 24.
PubMed 31973600Chatterjee NA, Tikkanen JT, Panicker GK, Narula D, Lee DC, Kentta T, Junttila JM, Cook NR, Kadish A, Goldberger JJ, Huikuri HV, Albert CM; PREDETERMINE Investigators. Simple electrocardiographic measures improve sudden arrhythmic death prediction in coronary disease. Eur Heart J. 2020 Jun 1;41(21):1988-1999. doi: 10.1093/eurheartj/ehaa177.
PubMed 32259257Silverman MG, Yeri A, Moorthy MV, Camacho Garcia F, Chatterjee NA, Glinge CSA, Tfelt-Hansen J, Salvador AM, Pico AR, Shah R, Albert CM, Das S. Circulating miRNAs and Risk of Sudden Death in Patients With Coronary Heart Disease. JACC Clin Electrophysiol. 2020 Jan;6(1):70-79. doi: 10.1016/j.jacep.2019.08.011. Epub 2019 Oct 30.
PubMed 31971908Sandhu RK, Dron JS, Liu Y, Moorthy MV, Chatterjee NA, Ellinor PT, Chasman DI, Cook NR, Khera AV, Albert CM. Polygenic Risk Score Predicts Sudden Death in Patients With Coronary Disease and Preserved Systolic Function. J Am Coll Cardiol. 2022 Aug 30;80(9):873-883. doi: 10.1016/j.jacc.2022.05.049.
PubMed 36007985Peek N, Hindricks G, Akbarov A, Tijssen JGP, Jenkins DA, Kapacee Z, Parkes LM, van der Geest RJ, Longato E, Sprague D, Taleb Y, Ong M, Miller CA, Shamloo AS, Albert C, Barthel P, Boveda S, Braunschweig F, Johansen JB, Cook N, de Chillou C, Elders P, Faxen J, Friede T, Fusini L, Gale CP, Jarkovsky J, Jouven X, Junttila J, Kautzner J, Kiviniemi A, Kutyifa V, Leclercq C, Lee DC, Leigh J, Lenarczyk R, Leyva F, Maeng M, Manca A, Marijon E, Marschall U, Merino JL, Mont L, Nielsen JC, Olsen T, Pester J, Pontone G, Roca I, Schmidt G, Schwartz PJ, Sticherling C, Suleiman M, Taborsky M, Tan HL, Tfelt-Hansen J, Thiele H, Tomaselli GF, Verstraelen T, Vinayagamoorthy M, Olesen KKW, Wilde A, Willems R, Wu KC, Zabel M, Martin GP, Dagres N. Sudden cardiac death after myocardial infarction: individual participant data from pooled cohorts. Eur Heart J. 2024 Nov 14;45(43):4616-4626. doi: 10.1093/eurheartj/ehae326.
PubMed 39378245Panicker GK, Narula DD, Albert CM, Lee DC, Kothari S, Goldberger JJ, Cook N, Schaechter A, Kim E, Moorthy MV, Pester J, Chatterjee NA, Kadish AH, Karnad DR. Validation of electrocardiographic criteria for identifying left ventricular dysfunction in patients with previous myocardial infarction. Ann Noninvasive Electrocardiol. 2021 Mar;26(2):e12812. doi: 10.1111/anec.12812. Epub 2020 Oct 30.
PubMed 33124739Venkateswaran RV, Moorthy MV, Chatterjee NA, Pester J, Kadish AH, Lee DC, Cook NR, Albert CM. Diabetes and Risk of Sudden Death in Coronary Artery Disease Patients Without Severe Systolic Dysfunction. JACC Clin Electrophysiol. 2021 Dec;7(12):1604-1614. doi: 10.1016/j.jacep.2021.05.014. Epub 2021 Jul 28.
PubMed 34332876Adabag S, Patton KK, Buxton AE, Rector TS, Ensrud KE, Vakil K, Levy WC, Poole JE. Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial. JAMA Cardiol. 2017 Jul 1;2(7):767-774. doi: 10.1001/jamacardio.2017.1413.
PubMed 28724134
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PRE-DETERMINE: Biologic Markers and MRI SCD Cohort Study
- ClinicalTrials.gov ID
- NCT01114269
- Acronym / sponsor ID
- 2007P000840
- Keywords
- Coronary Artery Disease, Sudden Cardiac Death, Myocardial Infarction, Percutaneous Coronary Intervention, Implantable Cardiac Defibrillator
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 5,764 participants (actual)
- Lead sponsor
- Brigham and Women's HospitalUniversity, hospital or other
- Collaborators
- Abbott Medical Devices, Northwestern University, Quintiles, Inc., Roche Diagnostic Ltd., National Heart, Lung, and Blood Institute (NHLBI), Cedars-Sinai Medical Center
- Study start
- Jul 2007 (actual)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 3 May 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective, multi-center cohort study of patients with a history of coronary artery disease (CAD) and documentation of either a prior myocardial infarction (MI) or mild to moderate left ventricular dysfunction (LVEF 35-50%). The primary objective of this study is to determine whether biologic markers and ECGs can be utilized to advance SCD risk prediction in patients with CHD and LVEF>30-35%. The overarching goal of the study is to identify a series of markers that alone or in combination specifically predict risk of arrhythmic death as compared to other causes of mortality among this at risk population of coronary heart disease (CHD) patients with preserved left ventricular ejection fraction (LVEF> 30-35%). If biologic or ECG markers are identified that can specifically predict risk of ventricular arrhythmias, then these markers may serve as relatively inexpensive methods to identify those at risk. The public health impact of identifying markers could be quite substantial, leading to more efficient utilization of ICDs and advances in our understanding of mechanisms underlying SCD.
Detailed description
The PRE-DETERMINE Study is a prospective, multi-center study of patients with a history of coronary artery disease (CAD) and documentation of either a prior myocardial infarction (MI) or mild to moderate left ventricular dysfunction (LVEF 35-50%). Patients were enrolled at 135 sites where information on baseline demographics, clinical characteristics, pertinent past medical history, lifestyle habits, cardiac test results, and medications were collected via electronic data capture. Electrocardiograms along with a blood sample was also collected at baseline, sent to central laboratories, and stored for future analyses. Contrast-enhanced magnetic resonance imaging (CE-MRI) scans were collected on a subset of patients and analyzed. Enrollment closed in November 2013 and patients are now being followed centrally by the Clinical Coordinating Center via mail/phone to document interim non-fatal arrhythmic events and cause-specific mortality. Questionnaires that inquire about intervening ICD implantations, ICD therapies, cardiac arrest, and other pertinent cardiovascular endpoints are mailed to participants every six months, and follow-up telephone calls are made to non-responders. Study endpoints are being confirmed through review of medical records, interviews with next-of-kin, and autopsy reports, if available.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants have been recruited throughout multicenter sites participating in the PRE-DETERMINE Cohort Study. Patients with a history of coronary artery disease and documentation of either a prior myocardial infarction (MI) or mild to moderate left ventricular dysfunction (LVEF 35-50%) have been enrolled. The clinical study staff at each site, which was either a research nurse, fellow, or physician approached eligible patients to discuss their potential participation.
Key inclusion criteria (16 listed)
- Evidence of Coronary Artery Disease (CAD) a or documented prior Myocardial Infarction.
- LVEF >35% by any current standard evaluation technique (e.g.,) echocardiogram, MUGA, angiography). 2.1. Patients who have an LVEF between 30-35% and NYHA Class I heart failure who do not have history of ventricular tachyarrhythmias,or inducible ventricular tachycardia during electrophysiological (EP) testing can be enrolled.
- If documented prior MI is not present, evidence of mild-moderate systolic Left Ventricular Dysfunction with an EF >35- ≤50% as measured by any current standard screening technique (e.g.,echocardiogram, MUGA, angiography) must be present.
- Patients aged 18 years or above
Key exclusion criteria (11 listed)
- History of cardiac arrest or spontaneous or inducible sustained VT (15 beats or more at a rate of 120 BPM or greater - the occurrence of cardiac arrest or spontaneous VT in the setting of an acute MI is not considered an exclusion).
- Unexplained syncope
- Current or planned implantable cardiac defibrillator (ICD)
- Any condition other than cardiac disease that, in the investigator's judgment, would seriously limit life expectancy (poor survival)
- Metastatic cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Sudden and/or arrhythmic cardiac death or resuscitated ventricular fibrillation.
Time frame: Median follow-up estimated to be 10.7 years
A definite sudden cardiac death (SCD) is defined as a death or fatal cardiac arrest occurring within 1 hour of symptom onset or the presence of autopsy consistent with SCD (e.g. acute coronary thrombosis). Probable SCD is defined as an unwitnessed death or death during sleep where the participant was observed to be symptom-free within the preceding 24 hours. Arrhythmic death is defined as the abrupt spontaneous collapse of circulation without antecedent circulatory or neurologic impairment. Deaths classified as non-arrhythmic are not included in the primary endpoint regardless of timing. Resuscitated ventricular fibrillation is defined as out-of-hospital cardiac arrests with documented VF and/or use of external electrical defibrillation for resuscitation.
5 secondary outcomes
ICD Shock
Time frame: Median follow-up estimated to be 10.7 years
ICD Implantation
Time frame: Median follow-up estimated to be 10.7 years
Total Cardiac Mortality
Time frame: Median follow-up estimated to be 10.7 years
Total Mortality
Time frame: Median follow-up estimated to be 10.7 years
Non-Sudden or Arrhythmic Causes of Mortality
Time frame: Median follow-up estimated to be 10.7 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2025.
- Results publication: PubMed 29801082Chatterjee NA, Moorthy MV, Pester J, Schaecter A, Panicker GK, Narula D, Lee DC, Goldberger JJ, Kadish A, Cook NR, Albert CM; PRE-DETERMINE Study Group. Sudden Death in Patients With Coronary Heart Disease Without Severe Systolic Dysfunction. JAMA Cardiol. 2018 Jul 1;3(7):591-600. doi: 10.1001/jamacardio.2018.1049.
- Results publication: PubMed 31973600Lee DC, Albert CM, Narula D, Kadish AH, Panicker GK, Wu E, Schaechter A, Pester J, Chatterjee NA, Cook NR, Goldberger JJ. Estimating Myocardial Infarction Size With a Simple Electrocardiographic Marker Score. J Am Heart Assoc. 2020 Feb 4;9(3):e014205. doi: 10.1161/JAHA.119.014205. Epub 2020 Jan 24.
- Results publication: PubMed 32259257Chatterjee NA, Tikkanen JT, Panicker GK, Narula D, Lee DC, Kentta T, Junttila JM, Cook NR, Kadish A, Goldberger JJ, Huikuri HV, Albert CM; PREDETERMINE Investigators. Simple electrocardiographic measures improve sudden arrhythmic death prediction in coronary disease. Eur Heart J. 2020 Jun 1;41(21):1988-1999. doi: 10.1093/eurheartj/ehaa177.
- Results publication: PubMed 31971908Silverman MG, Yeri A, Moorthy MV, Camacho Garcia F, Chatterjee NA, Glinge CSA, Tfelt-Hansen J, Salvador AM, Pico AR, Shah R, Albert CM, Das S. Circulating miRNAs and Risk of Sudden Death in Patients With Coronary Heart Disease. JACC Clin Electrophysiol. 2020 Jan;6(1):70-79. doi: 10.1016/j.jacep.2019.08.011. Epub 2019 Oct 30.
- Results publication: PubMed 36007985Sandhu RK, Dron JS, Liu Y, Moorthy MV, Chatterjee NA, Ellinor PT, Chasman DI, Cook NR, Khera AV, Albert CM. Polygenic Risk Score Predicts Sudden Death in Patients With Coronary Disease and Preserved Systolic Function. J Am Coll Cardiol. 2022 Aug 30;80(9):873-883. doi: 10.1016/j.jacc.2022.05.049.
- Results publication: PubMed 39378245Peek N, Hindricks G, Akbarov A, Tijssen JGP, Jenkins DA, Kapacee Z, Parkes LM, van der Geest RJ, Longato E, Sprague D, Taleb Y, Ong M, Miller CA, Shamloo AS, Albert C, Barthel P, Boveda S, Braunschweig F, Johansen JB, Cook N, de Chillou C, Elders P, Faxen J, Friede T, Fusini L, Gale CP, Jarkovsky J, Jouven X, Junttila J, Kautzner J, Kiviniemi A, Kutyifa V, Leclercq C, Lee DC, Leigh J, Lenarczyk R, Leyva F, Maeng M, Manca A, Marijon E, Marschall U, Merino JL, Mont L, Nielsen JC, Olsen T, Pester J, Pontone G, Roca I, Schmidt G, Schwartz PJ, Sticherling C, Suleiman M, Taborsky M, Tan HL, Tfelt-Hansen J, Thiele H, Tomaselli GF, Verstraelen T, Vinayagamoorthy M, Olesen KKW, Wilde A, Willems R, Wu KC, Zabel M, Martin GP, Dagres N. Sudden cardiac death after myocardial infarction: individual participant data from pooled cohorts. Eur Heart J. 2024 Nov 14;45(43):4616-4626. doi: 10.1093/eurheartj/ehae326.
- Results publication: PubMed 33124739Panicker GK, Narula DD, Albert CM, Lee DC, Kothari S, Goldberger JJ, Cook N, Schaechter A, Kim E, Moorthy MV, Pester J, Chatterjee NA, Kadish AH, Karnad DR. Validation of electrocardiographic criteria for identifying left ventricular dysfunction in patients with previous myocardial infarction. Ann Noninvasive Electrocardiol. 2021 Mar;26(2):e12812. doi: 10.1111/anec.12812. Epub 2020 Oct 30.
- Results publication: PubMed 34332876Venkateswaran RV, Moorthy MV, Chatterjee NA, Pester J, Kadish AH, Lee DC, Cook NR, Albert CM. Diabetes and Risk of Sudden Death in Coronary Artery Disease Patients Without Severe Systolic Dysfunction. JACC Clin Electrophysiol. 2021 Dec;7(12):1604-1614. doi: 10.1016/j.jacep.2021.05.014. Epub 2021 Jul 28.
- Derived from this study: PubMed 28724134Adabag S, Patton KK, Buxton AE, Rector TS, Ensrud KE, Vakil K, Levy WC, Poole JE. Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial. JAMA Cardiol. 2017 Jul 1;2(7):767-774. doi: 10.1001/jamacardio.2017.1413.
- Cardiac ArrestLink provided by the sponsor.
- Coronary Artery DiseaseLink provided by the sponsor.
- Pacemakers and Implantable DefibrillatorsLink provided by the sponsor.
- U.S. FDA ResourcesLink provided by the sponsor.
- Heart DiseaseLink provided by the sponsor.
- PRE-DETERMINE Study WebsiteLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Coronary Artery Disease
Not yet recruitingPhase 1/2
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)
Heterozygous Familial Hypercholesterolemia (HeFH)
Active, not recruitingPhase 3
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
Coronary Artery Disease
RecruitingObservational study
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
Metabolic Disease, Obesity
Active, not recruiting
Troponin in Acute Chest Pain to Risk Stratify and Guide EffecTive Use of Computed Tomography Coronary Angiography
Coronary Artery Disease
Recruiting
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
Cardiovascular Diseases, Myocardial Ischemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christine M Albert, M.D., M.P.H. principal investigator
Brigham and Women's Hospital
90 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease and Left Ventricular Dysfunction, run by Brigham and Women's Hospital at 90 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 90 sites in United States, Canada, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sudden and/or arrhythmic cardiac death or resuscitated ventricular fibrillation. (time frame: Median follow-up estimated to be 10.7 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01114269, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2025.